- Motley Fool•11 minutes ago
Has the market overestimated the odds of success for Tesaro's fancy new cancer drug?
Biotech M&A activity has fallen.
- Motley Fool•4 days ago
Tesaro has set the price of its newly launched PARP inhibitor, Zejula, at nearly $10,000 per month.
TSRO : Summary for TESARO, Inc. - Yahoo Finance
Tesaro, Inc. (TSRO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||139.07 x 100|
|Ask||139.17 x 100|
|Day's Range||136.51 - 139.57|
|52 Week Range||36.68 - 192.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-17.05|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|